MASAI RCT shows Transpara safe for workload reduction Summary
We focus on improving breast cancer survival rates by detecting cancers earlier and making treatment more effective and less intense.
FDA cleared for use on all major 2D and 3D mammography systems.
Supporting you through your AI journey
Trusted in more than 30 countries
FDA cleared and CE marked for 2D and 3D mammography
The most independent peer reviewed publications in breast AI
Proven multivendor compatibility
Integrated with most workstations
Experience the benefit of our continuously evolving deep learning algorithm
Accuracy.
Workload Reduction.
Results.
"Transpara has the potential to detect specific cancers earlier. I can think of 1-2 recent cases with calcifications, where Transpara detected a cancer earlier that was not easily visible on a mammogram."
"Transpara increases my confidence and efficiency going through a screening mammography session. I have more focus especially with the higher risk cases thanks to their Intuitive Triage software."
"I use Transpara all the time, and won't read another 3D mammogram without it. The product fits seamlessly into our workflow, and we have found over time it has increased our mammography workflow. Thanks to the technology's score card we are also able to focus on those high risk patients first, and get those patients the care they may need faster."
“Transpara may allow discriminating studies, which require more attention and selection of those, which may be handled with single reading for example. It may thus contribute significantly to both risk adapted screening and optimum assignment of resources."
"We are at the forefront of one of the first prospective studies with Transpara. As we will implement Transpara in a real-life screening setting in Ostergotland County, we aim to improve the quality of the breast cancer screening program while at the same time safely reduce the workload of breast radiologists."
Client undergoes mammogram
Transpara analyses mammogram scan
Radiologist reads with support from Transpara, increasing confidence in decision
Make more accurate and consistent decisions
World’s Leading Breast AI Software, Transpara Surpasses 5 Million Mammograms and 1 Million Tomosynthesis Studies Analyzed to Support Radiologists Reading
Read moreThe Most Clinically Validated Breast AI Featured in 4 Significant Peer-Reviewed Studies in Past 6 Months, Better Workflow to Increase
Read moreOur Nijmegen office was visited by a Netherlands-based news crew the week of August 1. What was the big news?
Read moreRandomized Controlled Trial for Breast AI as Second Reader: Preliminary Results Published in The Lancet Oncology Transpara®-assisted workflow helps
Read morePress Release From Lancet Oncology: The AI in use is Transpara First randomised trial finds AI-supported mammography screening is safe
Read moreResearch from Mayo Clinic and UCSF find that the combination of Transpara ® Exam Score with Volpara TruDensity® can predict
Read more
